Navigation Links
Phlo Reports Sharp Revenue Increase
Date:2/21/2008

JACKSONVILLE, Fla., Feb. 21 /PRNewswire-FirstCall/ -- Phlo Corporation (Pink Sheets: PHLC) (the "Company") reported revenue during the three and nine-month periods ended December 31, 2007 of $190,072 and $320,256, respectively, as compared with revenue during the three and nine-month periods ended December 31, 2006 of $3,100 and $4,723, respectively. This represents increases in revenue of $186,972 and $315,533 for the three and nine months ended December 31, 2007, respectively, as compared with the comparable periods ended December 31, 2006. Further, revenue significantly increased from $116,560 during the three months ended September 30, 2007 to $190,072 during the three months ended December 31, 2007. The Company's gross profit margin for the nine-month period ended December 31, 2007 was 49%. The report was made on the Company's Form 10-QSB which was filed with the Securities and Exchange Commission last week and which provides additional detail related to the Company's operating results for the periods covered.

The Company noted that this significant increase in revenue occurred during, typically, one of the worst quarters of the beverage year for sales because of cold weather and holidays. In addition, this revenue increase occurred in spite of the Company's transition from 17-ounce packaging to new 20-ounce bottles for its AQISS(TM) vitality beverage product. This transition, in effect, kept AQISS(TM) out of the market for a substantial period during the quarter ended December 31, 2007.

The Company incurred cost of sales during the three and nine-month periods ended December 31, 2007 of $132,149 and $164,671, respectively, as compared with cost of sales during the comparative three and nine-month periods of 2006 of $3,045 and $3,213 respectively.

AQISS(TM) features the Company's Instant Nano Hydration and Cell Armor technologies, providing instant, direct delivery of rehydration and cell- repair-and-protection payloads into the bloodstream beginning through the membranes of the mouth. These Instant Nano Hydration and Cell Armor technologies help provide sustained wellness necessary for life's performances and vigorous longevity. In addition, the Company's nano-encapsulation technology prevents the destruction of its active payloads in the stomach.

Phlo is a biotechnology company and a manufacturer and marketer of products (primarily liquids) containing patented and patent-pending biotechnologies. Phlo is focusing its technology generation and acquisition efforts on those technologies related to enhancing cognition and personal performance, reducing the effects of aging, and preventing or ameliorating cancer.

Certain statements made herein that are not historical constitute "forward-looking" statements within the meaning of the Private Litigation Reform Act of 1995 and may contain words such as "anticipate," "believe," "expect," "future," "may," "will," "should," "plan," "projected," "intend," and similar expressions to identify such forward-looking statements. Such statements are based on a number of assumptions and on information and estimates supplied to Phlo Corporation by sources currently available to it. Such assumptions and estimates are subject to uncertainties, contingencies, and other factors, many of which are beyond Phlo Corporation's control. Actual results may differ materially from the statements set forth above.


'/>"/>
SOURCE Phlo Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Novocell Reports Successful Use of Stem Cells to Generate Insulin in Mice
2. Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook
3. Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007
4. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
5. Amsterdam Molecular Therapeutics Reports Full Year Results 2007
6. Medivation Reports Year-End 2007 Financial Results and Pipeline Progress
7. United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results
8. Favrille Reports Fourth Quarter and Year End 2007 Financial Results
9. JADO Reports Clinical Proof of Concept With Raft Modulator in Atopic Dermatitis
10. OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) is Feasible in Acute Myocardial Infarction Patients, American Heart Journal Paper Reports
11. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... Scientists propose in Nature blocking ... Gaucher and maybe other lysosomal storage diseases as a ... current therapies. An international research team led ... also included investigators from the University of Lübeck in ... 22. The study was conducted in mouse models of ...
(Date:2/22/2017)... Yorba Linda, Ca (PRWEB) , ... February 22, ... ... interactive virtual events for tech innovators, engineers, and scientists from around the world, ... event will place on February 22 and 23, 2017. This premier, online-only conference ...
(Date:2/22/2017)... , Feb. 22, 2017 Origin (Origin Agritech, LLC, a ... and seed provider, and Arcadia (Arcadia Biosciences, ... develops and commercializes agricultural productivity traits and nutritional products, today announced ... biotechnology product developed in China to ... trials. ...
(Date:2/22/2017)... ... February 22, 2017 , ... Pharma and biotech consulting ... European director. Operating from Pennside’s Zurich headquarters, Pennside Partners, GmbH, Mr. Perkins brings ... after more than a decade with leading market research firm, GfK. He began ...
Breaking Biology Technology:
(Date:2/10/2017)... Research and Markets has announced the addition of ... Commercial Aspects" to their offering. ... Biomarkers play an important ... selection of treatment as well for monitoring the results. There ... modern medicine. Biochip/microarray technologies and next generation sequencing are also ...
(Date:2/8/2017)... Inc. (NASDAQ: AWRE ), a leading supplier of ... quarter and year ended December 31, 2016. ... compared to $6.9 million in the same quarter last year. ... million compared to $2.6 million in the fourth quarter of ... $0.5 million, or $0.02 per diluted share, which compares to ...
(Date:2/8/2017)... 7, 2017 Report Highlights The ... from $8.3 billion in 2016 at a compound annual ... Report Includes - An overview of the global ... with data from 2015 and 2016, and projections of ... of the market on the basis of product type, ...
Breaking Biology News(10 mins):